Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Sponsor
Second Affiliated Hospital of Nanchang University
Study ID
NCT04944069
Status
Unknown

Conditions

  • EGFR Activating Mutation
  • Leptomeningeal Metastasis
  • NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Almonertinib — DRUG
    110 mg oral once daily
  • Bevacizumab — DRUG
    15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)

Study Details

A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Key Dates

First listed
Jun 29, 2021
Start date
Jul 31, 2021
Status verified
May 2021
Primary completion
Mar 31, 2024
Completion
Mar 31, 2025

Study Design

Enrollment
69 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Almonertinib With Bevacizumab
    Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: From date of enrollment until the date of death, up to 2 years ]

Central Contacts

Related Studies